Stay updated on Nivolumab Plus Ipilimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for CheckMate 592 is displayed, with details about the nivolumab–ipilimumab study, participation criteria, study locations, and measured outcomes.SummaryDifference66%

- Check13 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study record continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA notice announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence,” and the site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1; the page remains a 403 error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error page, replacing the previously visible study record details for the trial and offering a Home link instead.SummaryDifference18%

- Check62 days agoChange DetectedThe page now shows Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates an updated version of the study page document.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Plus Ipilimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page.